(Source: Pharmaceutical Business Review 2014-5-27）
Taiwanese pharmaceutical firm Orient EuroPharma and Swiss biopharmaceutical firm Debiopharm Group (Debiopharm) have entered into a distribution agreement for the commercialization and promotion of Pamorelin in South East Asia.
As part of the agreement, the firms have announced the launch of Pamorelin in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Under the deal, Orient acquires exclusive marketing and sales rights for Pamorelin in Singapore.
Pamorelin is exported in finished bulk from Debiopharm Research and Manufacturing to Orient EuroPharma.
The drug will be made available primarily to urologists and oncologists across Singapore.
Orient is mainly focused on marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore and Philippines.
Orient EuroPharma president of Pharmaceutical Business Unit JP Chang said that it is great to cooperate with Debiopharm for introducing the new drug to South East Asian territories.
“Orient EuroPharma owns strong connections and an experienced team in the Oncology field; this partnership will provide another therapy option for physicians to treat prostate cancer patients,” Chang said.
Debiopharm Group delegate of the Board Thierry Mauvernay said the collaboration opens up an important new market for the companys backbone therapy of advanced prostate cancer.
“After successful launch in 74 countries, we look forward to bringing Pamorelin to several South East Asian markets, together with Orient EuroPharma,” Mauvernay said.
The company said that triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH).
The Swiss firm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate.
More Information on Pharmaceutical Business Review